Pandemic Alliance Munich (PAM)

Ihr Kontakt

Regina Bach

Project Coordination Pandemic Alliance Munich

Mehr zum Thema

Governance und Organisation

Die Pandemic Alliance Munich ist eine öffentlich-private Initiative, die von BioM koordiniert wird. Das Konsortium umfasst derzeit führende wissenschaftliche und industrielle Partner.

Kooperationsmöglichkeiten

Das Netzwerk und das Projektportfolio werden kontinuierlich ausgebaut, um Innovationen und Kooperationen zu stärken.

Kontakt aufnehmen

Collaborating to Drive Innovation in Pandemic Preparedness and Health Resilience

Die Pandemic Alliance Munich (PAM) ist eine Initiative zur Vorbereitung auf zukünftige Pandemie- und Infektionsereignisse. Sie vernetzt Akteure aus Forschung, Klinik, KMU und Industrie, um interdisziplinäre Kompetenzen gezielt zu bündeln und Innovationen zu fördern.

Ziel der Pandemic Alliance Munich ist, durch enge Zusammenarbeit und Vernetzung die wissenschaftlichen, technologischen und organisatorischen Grundlagen sowie eine schnelle und koordinierte Reaktion auf Infektionsereignisse zu stärken. Der Fokus liegt auf dem gesamten Pandemiezyklus von Prävention, Detektion, Diagnostik und Therapie bis hin zur klinischen und strukturellen Umsetzung.

Thematische Schwerpunkte:

  • Früherkennung und Diagnostik
    Entwicklung und Validierung innovativer Technologien zur Früherkennung und präzisen Diagnose von Pathogenen mit Pandemiepotenzial.

  • Virus- und Immunforschung
    Untersuchung zentraler Virus- und Immunmechanismen zur Prädiktion von Reaktionsmustern bei Infektionskrankheiten.

  • Prädiktive Marker für Therapieansätze
    Etablierung prädiktiver Marker zur Patientenstratifizierung und zur Optimierung therapeutischer und klinischer Versorgungsstrategien.

  • Kooperations- und Transferstrukturen
    Aufbau von Kooperationsmodellen für ein geeignetes Management von Infektionsereignissen.

“Within the Pandemic Alliance Munich, we are joining forces to improve the diagnosis of pandemic viruses and microbes, as well as our understanding of the pathology they cause. This will help us to be better prepared for a potential new pandemic and to combat biothreats involving the abuse of viruses to threaten our society.“
Prof. Dr. Ulrike Protzer
Director, Institute of Virology, Technical University of Munich / Helmholtz Munich

Aktuelle Verbundprojekte

Die Pandemic Alliance Munich bündelt derzeit folgende Verbundprojekte

Diagnostic Toolbox for Pandemic Parameters (PaPrep1)

Consortia: LMU Klinikum, Fraunhofer ITMP/Location IIP, Roche

Project Period: 2022-2025

PaPrep1 aims to identify pathogens with pandemic potential and prepare for emerging threats ("disease X"). It spans the development of test prototypes, to enable rapid implementation of diagnostically established mass testing in an emergency situation.

Diagnostic strategies and tools for pandemic management (PaPrep2)

Consortia: LMU Klinikum, Fraunhofer ITMP/Location IIP, Roche

Project Period: 2025-2028

Pursues PaPrep1, to broaden the scope of assay application and methods, where a pathogen priority list was established and a preliminary toolbox for the fast development of diagnostic prototypes against enveloped and non-enveloped viruses, gram-positive spore-forming bacteria and human-pathogenic fungi was established.

Prevention of Pandemic-infection-associated Pathology Munich – P3M

Consortia: Klinikum der Technischen Universität München (TUM Klinikum), Roche Diagnostics, Technische Universität München (TUM), Helmholtz Munich

Project Period: 2025-2028

PAM-P3M investigates organ damage caused by pandemic viruses, using the hepatitis B virus as a model. It develops viral and immunological cure biomarkers to enable early diagnosis, prognosis, and patient stratification, with transferability to future pandemic pathogens.

Abstract:

Emerging and pandemic viral infections can cause severe, often immune mediated organ damage. A key challenge is the early identification of infections and reliable prediction of disease outcome, as robust predictive biomarkers are still lacking. Using chronic hepatitis B as a model, this consortium addresses this gap through the systematic development and validation of novel viral and immunological cure biomarkers. Although established markers such as HBV DNA and HBsAg are available, they provide an incomplete picture of viral activity and immune control, particularly in specific patient subgroups.

PAM-P3M aims to identify cure biomarkers that discriminate between protective immune responses associated with controlled infection and insufficient immune responses leading to viral persistence, chronic infection, and severe organ damage. To this end, viral parameters, as well as immunological markers, are analyzed individually and in combination and developed into predictive testing systems. Innovative pre analytical approaches, such as antibody–antigen complex dissociation, together with multiparametric immune profiling, enable a more precise assessment of patient immune status.

Close collaboration between academic research, clinical expertise, and pharmaceutical and biotechnology partners supports the translational implementation of the results into commercial diagnostic assays. The concepts and test systems developed are designed to be transferable within the Pandemic Alliance Munich to other pathogens with pandemic potential, enabling rapid scaling of predictive diagnostics in future pandemic scenarios.

 

DIScover novel TB Diagnostics

Consortia: Klinikum LMU, Roche, TUM

Project Period: 2025-2028

DIS-TB evaluates non-sputum-based biomarkers for improved diagnostics of tuberculosis in children, pregnant women and HIV-infected patients from endemic regions. Comprehensive pathogen and host markers from various sample types are analyzed to identify reliable candidates for later clinical application.